Literature DB >> 16237101

MARCO is the major binding receptor for unopsonized particles and bacteria on human alveolar macrophages.

Mohamed S Arredouani1, Aiyappa Palecanda, Henry Koziel, Yuh-Ching Huang, Amy Imrich, Timothy H Sulahian, Yao Yu Ning, Zhiping Yang, Timo Pikkarainen, Marko Sankala, Sara O Vargas, Motohiro Takeya, Karl Tryggvason, Lester Kobzik.   

Abstract

Alveolar macrophages (AMs) avidly bind and ingest inhaled environmental particles and bacteria. To identify the particle binding receptor(s) on human AMs, we used functional screening of anti-human AM hybridomas and isolated a mAb, PLK-1, which inhibits AM binding of unopsonized particles (e.g., TiO2, latex beads; 63 +/- 5 and 67 +/- 4% inhibition, respectively, measured by flow cytometry; n = 11) and unopsonized bacteria ( approximately 84 and 41% inhibition of Escherichia coli and Staphylococcus aureus binding by mAb PLK-1, respectively). The PLK-1 Ag was identified as the human class A scavenger receptor (SR) MARCO (macrophage receptor with collagenous structure) by observing specific immunolabeling of COS cells transfected with human MARCO (but not SR-AI/II) cDNA and by immunoprecipitation by PLK-1 of a protein of appropriate molecular mass (approximately 70 kDa) from both normal human bronchoalveolar lavage cells (>90% AMs) and human MARCO-transfected COS cells. PLK-1 also specifically inhibited particle binding by COS cells, only after transfection with human MARCO cDNA. Immunostaining showed specific labeling of AMs within human lung tissue, bronchoalveolar lavage samples, as well as macrophages in other sites (e.g., lymph node and liver). Using COS transfectants with different truncated forms of MARCO, allowed epitope mapping for the PLK-1 Ab to MARCO domain V between amino acid residues 420 and 431. A panel of Abs to various SRs identified expression on AMs, but failed to inhibit TiO2 or S. aureus binding. The data support a dominant role for MARCO in the human AM defense against inhaled particles and pathogens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237101     DOI: 10.4049/jimmunol.175.9.6058

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  70 in total

1.  Acute lung inflammation in Klebsiella pneumoniae B5055-induced pneumonia and sepsis in BALB/c mice: a comparative study.

Authors:  Vijay Kumar; Sanjay Chhibber
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

2.  Scavenger receptors clear the air.

Authors:  Edward M Postlethwait
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

3.  Immunomodulators targeting MARCO expression improve resistance to postinfluenza bacterial pneumonia.

Authors:  Muzo Wu; John G Gibbons; Glen M DeLoid; Alice S Bedugnis; Rajesh K Thimmulappa; Shyam Biswal; Lester Kobzik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-04-13       Impact factor: 5.464

4.  Particulate matter promotes in vitro receptor-recognizable low-density lipoprotein oxidation and dysfunction of lipid receptors.

Authors:  Natalia Manzano-León; Jaime Mas-Oliva; Laura Sevilla-Tapia; Rocío Morales-Bárcenas; Jesús Serrano; Marie S O Neill; Claudia M García-Cuellar; Raúl Quintana; Inés Vázquez-López; Alvaro R Osornio-Vargas
Journal:  J Biochem Mol Toxicol       Date:  2013-01-07       Impact factor: 3.642

5.  Therapeutic inflammatory monocyte modulation using immune-modifying microparticles.

Authors:  Daniel R Getts; Rachael L Terry; Meghann Teague Getts; Celine Deffrasnes; Marcus Müller; Caryn van Vreden; Thomas M Ashhurst; Belal Chami; Derrick McCarthy; Huiling Wu; Jin Ma; Aaron Martin; Lonnie D Shae; Paul Witting; Geoffrey S Kansas; Joachim Kühn; Wali Hafezi; Iain L Campbell; David Reilly; Jana Say; Louise Brown; Melanie Y White; Stuart J Cordwell; Steven J Chadban; Edward B Thorp; Shisan Bao; Stephen D Miller; Nicholas J C King
Journal:  Sci Transl Med       Date:  2014-01-15       Impact factor: 17.956

6.  MARCOing monocytes for elimination.

Authors:  Lester Kobzik; Filip K Swirski
Journal:  Sci Transl Med       Date:  2014-01-15       Impact factor: 17.956

7.  Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.

Authors:  Norimasa Matsushita; Hiroshi Komine; Annabelle Grolleau-Julius; Shari Pilon-Thomas; James J Mulé
Journal:  Cancer Immunol Immunother       Date:  2010-01-08       Impact factor: 6.968

8.  Divergence of macrophage phagocytic and antimicrobial programs in leprosy.

Authors:  Dennis Montoya; Daniel Cruz; Rosane M B Teles; Delphine J Lee; Maria Teresa Ochoa; Stephan R Krutzik; Rene Chun; Mirjam Schenk; Xiaoran Zhang; Benjamin G Ferguson; Anne E Burdick; Euzenir N Sarno; Thomas H Rea; Martin Hewison; John S Adams; Genhong Cheng; Robert L Modlin
Journal:  Cell Host Microbe       Date:  2009-10-22       Impact factor: 21.023

9.  In vivo uptake of inhaled particles by airway phagocytes is enhanced in patients with mild asthma compared with normal volunteers.

Authors:  J C Lay; N E Alexis; K L Zeman; D B Peden; W D Bennett
Journal:  Thorax       Date:  2008-12-03       Impact factor: 9.139

10.  Heterogeneity in macrophage phagocytosis of Staphylococcus aureus strains: high-throughput scanning cytometry-based analysis.

Authors:  Glen M DeLoid; Timothy H Sulahian; Amy Imrich; Lester Kobzik
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.